ALBIGLUTIDE
What Is ALBIGLUTIDE?
Albiglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. It is a long-acting analog with a half-life of approximately 5 days, created by fusing GLP-1 to human albumin, which provides extended duration of action. Albiglutide works by stimulating insulin secretion in response to elevated blood glucose, suppressing glucagon release, slowing gastric emptying, and promoting satiety.
ALBIGLUTIDE Research & Studies
01 Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial ▸
The Harmony Outcomes trial demonstrated that albiglutide significantly reduced major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease compared to placebo.
View Study (PubMed)02 Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials ▸
Meta-analysis of cardiovascular outcome trials showed GLP-1 receptor agonists, including albiglutide, provide significant benefits for cardiovascular events, mortality, and kidney outcomes in type 2 diabetes patients.
View Study (PubMed)03 Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial ▸
Albiglutide demonstrated significant reductions in myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and established cardiovascular disease.
View Study (PubMed)04 GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art ▸
Comprehensive review showing albiglutide is administered once weekly, shares common mechanisms with other GLP-1 RAs including augmentation of insulin secretion, suppression of glucagon, and delayed gastric emptying.
View Study (PubMed)05 The safety of albiglutide for the treatment of type 2 diabetes ▸
Albiglutide has significantly fewer gastrointestinal side effects compared to other GLP-1 receptor agonists and appears safe across all stages of renal failure, though concerns exist about pancreatitis cases and injection site reactions.
View Study (PubMed)06 Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes ▸
Albiglutide consistently lowered postprandial glucose levels after each meal in addition to reducing fasting plasma glucose at clinically relevant doses of 30-64 mg.
View Study (PubMed)07 Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity ▸
GLP-1 analogs including albiglutide slow gastric emptying and increase gastric volumes, which contributes to reduced postprandial glycemia and promotes satiety.
View Study (PubMed)08 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus ▸
Long-acting GLP-1 receptor agonists like albiglutide provide continuous receptor activation and primarily lower fasting glucose through sustained insulin secretion, while short-acting agents mainly affect postprandial glucose.
View Study (PubMed)ALBIGLUTIDE User Reviews & Experiences
*Based on large scale analysis of publicly available user experiences
Limited Reddit user experiences available for albiglutide. As a prescription GLP-1 receptor agonist primarily used for diabetes management, community discussions are sparse compared to more accessible supplements.
ALBIGLUTIDE Benefits, Dosage & Side Effects
- Glycemic Control: Reduces HbA1c by approximately 1% through enhanced insulin secretion and glucagon suppression
- Cardiovascular Protection: Significantly reduces major adverse cardiovascular events including myocardial infarction in patients with established heart disease
- Gastric Effects: Slows gastric emptying and increases satiety, contributing to postprandial glucose control
- Minimal Weight Impact: Provides modest weight reduction effects compared to other GLP-1 receptor agonists like liraglutide
- Cardiovascular Outcomes: Demonstrates significant reductions in cardiovascular events in high-risk patients with type 2 diabetes
- Glucose Reduction: Effectively lowers both fasting and postprandial plasma glucose at doses of 30-64 mg weekly
- Comparative Efficacy: Shows slightly less HbA1c reduction and weight loss compared to some competitor GLP-1 agonists like liraglutide
- Renal Safety: Proven safe and effective across all stages of renal failure without dose adjustment requirements
- Standard Dose: Once-weekly subcutaneous injection of 30-50 mg as maintenance therapy
- Duration of Action: Half-life of approximately 5 days allows for weekly administration
- Clinical Range: Studied doses range from 30-64 mg weekly in phase 2 and 3 trials
- Administration: Administered via subcutaneous injection using pre-filled pen device
- Gastrointestinal Tolerance: Significantly fewer GI side effects (nausea, vomiting) compared to other GLP-1 receptor agonists, with rates similar to placebo
- Injection Site Reactions: Reported in up to 2% of patients, occasionally leading to treatment discontinuation
- Pancreatitis Concern: Imbalance of pancreatitis cases noted in approval program, though overall incidence remains low
- Hypoglycemia Risk: Low risk when used as monotherapy, but increased risk when combined with sulfonylureas or insulin
- Prescription Status: Available by prescription for type 2 diabetes management in patients requiring injectable therapy
- Market Status: Originally marketed but subsequently discontinued by manufacturer in 2017 despite proven efficacy and safety profile
- Clinical Use: Primarily studied and used in patients with type 2 diabetes who have not achieved glycemic control with oral medications
How Our Community Rates It?
Sign in to leave a review